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Background: Incomplete P2Y12-inhibition during clopidogrel treatment is
associated with increased cardiovascular events and mortality after coronary
intervention.
The aim of this study was to evaluate the effect of high-dose clopidogrel
continuation treatment on the development of MACCE in patients with Cyto-
chrome P450 2C19*2 Loss-of-Function Allele.
Methods: Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results: The use of a double maintenance dose of clopidogrel (150 mg)
was noted in 27% of cases, similarly in both study groups (28.6% in the non-
mutated versus 21.7 % in the mutant group (p=0.5).
This attitude was especially observed in diabetic patients, if drug-eluting
stent is used and in case of complex angioplasty (77% of patients on double
dose of clopidogrel are diabetics and 70% were implanted with a drug-eluting
stent).
The use of a double dose of clopidogrel results in a non significant
decrease in the occurrence of MACE in the non mutated group (10.9% vs 0%,
p=0.17) and has no effect in the mutated group (22% in a double dose of clop-
idogrel versus 20% p=0, 91).
Conclusion: Our study showed no relationship between the use of a double
dose of clopidogrel and reduced occurrence of MACE, irrespective of the
genetic profile studied.
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Objective: To investigate the determinants and the prognostic capacity of
fragmented QRS on a 12-lead ECG in patients with acute myocardial infarc-
tion.
Patients and methods: Prospective cohort of 307 consecutive patients
with AMI. Main outcomes measure: in-hospital adverse outcomes, thirty-day
and one year mortality. 
Results: 163 (53%) were found without fQRS (No fQRS group). 144
(47%) presented a fQRS on the first 36 hours 12-lead ECG, which was per-
sistent in 107 patients (persistent fQRS group) and non persistent in 37
patients (non-persistent fQRS group). Despite similar demographic features,
clinical presentation and reperfusion strategies, patients with a fragmented
QRS (transient or persistent) were older, more likely hypertensive and less
smoker were found among these groups. If in-hospital adverse outcomes were
similar between groups, interestingly we found a trend towards a greater like-
lihood of ventricular arrhythmias in the group without a fragmented QRS
when compared with other groups (12% vs. 5% vs. 4%, respectively,
p=0.054). An all-cause death at 30 days was similar in the three populations.
At one year’s follow-up, 45 (14.6%) patients had died from all causes and 30
(9.7%) from cardiovascular cause. The Kaplan Meier analysis revealed that
mortality was significantly higher in the fQRS group (persistent or not) than
in the non-fQRS group (30 (20%) vs. 15(9.2%) respectively, p=0.007). By
multivariate logistic regression analysis, age (p=0.008) and the presence of a
family history of CAD (p=0.043) were independent predictors of fQRS occur-
rence. In multivariate analysis six variables were significant predictors of all-
cause death at one year: age, DBP, glucose on admission, LVEF, treatment
with beta-blockers at the acute phase and presence of a fQRS.
Conclusions: The fQRS is an independent predictor of 1 year all cause
death after AMI, even after correction with age and LVEF, and It is associated
with lower event-free survival.
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Aims: Clopidogrel discontinuation after percutaneous coronary interven-
tion (PCI) with drug-eluting stent (DES) implantation has been reported to
correlate with stent thrombosis. Whether these events are a consequence of the
rebound phenomenon or a lack of protection in unhealed vessels is unclear.
This study aimed to determine the link between clopidogrel cessation and car-
diovascular events after PCI with DES. Methods and results: The population
included 1,903 patients who underwent PCI with DES implantation from 2003
to 2007. We compared patients who stopped their clopidogrel within the first
month (group 1, n=97), from one to six months (group 2, n=344), from six to
12 months (group 3, n=468), and after 12 months (group 4, n=994) following
the PCI. In each group, the composite of death, myocardial infarction and
stent thrombosis at 30 days and between 31 and 60 days after clopidogrel ces-
sation was indexed. Baseline characteristics were similar among groups. The
event rate observed in the 0-30 day interval following cessation was higher
only in group 1 (5.2%) compared to all other groups: 1.2% (group 2), 0.9%
(group 3) and 0.6% (group 4) (p=0.004). The event rates from 31 to 60 days
following cessation were low and similar among the four groups. When the
elapsed time between the index PCI and the clopidogrel cessation was anal-
ysed as a continuous variable, the probability of events occurring within the
first 30 days became similar to that observed in the 31-60 day interval fol-
lowing cessation after a minimum of 10.2 months. 
Conclusions: Cardiac events seen immediately after clopidogrel cessation
are not related to a rebound phenomenon, but are more likely influenced by
the lack of healing at the time of cessation, which decreases over time. This
increased risk related to the lack of healing seems to disappear after
10.2 months.
022
One-year outcome of everolimus vs. paclitaxel-eluting stents for the
treatment of unprotected left main lesions
Anouska Moynagh [Orateur] (1), Neus Salvatella (1), Olivier Darremont
(2), Thierry Lefèvre (1), Didier Carrié (3), Yves Louvard (1), Jean-Louis
Leymarie (2), Bernard Chevalier (1), Marie-Claude Morice (1), Philippe
Garot(1)
(1) Institut Hospitalier Jacques Cartier, Institut Cardiovasculaire Paris
Sud, Massy, France – (2) Clinique Saint-Augustin, Bordeaux, France – (3)
CHU Rangueil, Toulouse, France
Background: Coronary artery bypass surgery is recognised as the “gold
standard” treatment for unprotected left main (LM) stenosis. However,
advances in percutaneous coronary intervention techniques and the introduc-
tion of drug eluting stents have led to the acceptance of PCI as an alternative
strategy for complex lesions including LM lesions.
Methods: We performed a matched comparison of patients in the French
Left Main Taxus registry and the Left Main Xience registry undergoing
unprotected LM stenting with Taxus paclitaxel-eluting (PES) and Xience siro-
limus-eluting (SES) stents respectively, in 4 French centres. 172 patients were
matched according to Syntax score, stenosis involving the distal LM, provi-
sional side-branch T-stenting and use of one stent in the distal LM. 
Results: Patients were aged 69.5±11.3 years, 76.5 % of patients were
male. 25.3% of patients were diabetics and 27.3% had undergone previous
PCI. Mean Syntax score was 25.5±9.6. The distal LM was involved in 82%
and provisional SB T-stenting was performed in 91.1%.
The one- year follow-up results are shown in Table 1.
Patients were stratified according to the 3 SYNTAX score subgroups.
Patients with low SYNTAX score had similar outcomes for MACE at 1 year
(9.6% vs. 6.8%, p=0.67) for PES and EES respectively. Intermediate and high
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SYNTAX score subgroups demonstrated numerically higher MACE rates in
patients with PES compared to EES (15.3% vs. 5.1%) and (30.0% vs. 15.4%)
respectively.
Patients with low and intermediate SYNTAX scores had similar TLF out-
comes at 1 year. However, the high SYNTAX score group had a significantly
higher rate of TLF in the PES group (27.5% vs. 10.3%, p=0.01).
Cardiac death was higher in patients with an intermediate SYNTAX score
in PES patients (6.8% vs.0.0%, p=0.04) as was TVMI (8.5% vs. 0.0%,
p=0.02).
Conclusion: Unprotected LM stenting with EES is feasible, safe and more
effective in the mid term, than with PES with a reduction in MACE, TLF and
cardiac death at one year.
Table 1 – One- year follow-up results
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Objectives: The PACS-HIV study is designed to evaluate the 3-year prog-
nosis of acute coronary syndrome (ACS) in HIV-infected patients (HIV+) as
compared to HIV-uninfected patients (HIV-) in a prospective observational
study. We aim to present the long term 3-year follow-up.
Methods: We enrolled consecutively 103 HIV-infected and 195 HIV-unin-
fected patients with a first episode of ACS matched for age (± 5 years), sex,
and type of ACS. The primary endpoint was the rate of major adverse cardiac
and cerebral events (MACCE), comprising cardiac death, recurrent ACS,
recurrent coronary revascularization, and stroke. 
Results: The mean age of the cohort was 49.0 ± 9.4 years and 94% were
men. At baseline, coronary risk factors were well balanced and angiographic
features were not different between both groups. MACCE at 3-year are
depicted in Table. The rate of occurrence of first MACCE at 36-months was
similar in both groups (uivariate hazard ratio [HR]=1.4, 95% CI, 0.7-2.6).
However, recurrent ACS was more frequent in HIV+ group as compared with
HIV- group (univariate HR=3.4, 95% CI, 1.3-8.8). Stratified multivariate Cox
model showed that the only factor associated with the recurrence of ACS was
HIV status with HR 7.86 for HIV+ versus HIV- (95% CI, 1.2-50.6, p= 0.03).
Conclusion: HIV-infected patients had higher recurrence of ACS despite
similar coronary risk factors, clinical, and angiographic features at baseline of
a first episode of ACS as compared to HIV-uninfected patients. Specific sec-
ondary prevention may be warranted to alleviate this risk. 
Table – MACCE at 3-year 
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Purpose: Our aim was to assess the long term prognosis value of resting
HR in a contemporary large cohort of subjects with known CAD.
Methods: Among 834 consecutive male pts hospitalized in 2001-2004 for
coronary artery disease, HR was measured in 778 pts. The median follow-up
was 7.17 years. Total mortality was predicted with a Cox proportional hazard
model
Results: Mean age (SD) was 60.2 (8.1), 144 pts (18.4%) were diabetic,
mean glycaemia was 5.9 mmol/l (2.1), 155 pts (19.8%) were smokers, mean
blood pressure was 139 (20) / 84 (11) mmHg. Mean HDL cholesterol was 43
mg/dl (11), mean LDL cholesterol124 mg/dl (39) and median triglycerides
were 147 mg/dl IQR [109-197]. Mean Cockcroft-Gault creatinine clearance
was 87 ml/min and 11 pts (1.4%) had a severe chronic renal failure (lower
than 30 ml/min). Mean left ventricular ejection fraction was 0.53 (0.13).
88.5% were on antiplatelet therapy, 75.2% on beta-blocker, 66% on statin
therapy and 54.8% on ACE inhibitors or ARB.
40.5% of pts had HR < 60 bpm, 32% HR between 60 and 69 bpm and
27.5% had HR 70 bpm. The cumulative seven-year total mortality rate was
17.8%. In the HR < 60 bpm group, mortality rate was 11.1%, whereas it was
17.3% in the group with HR - 60 bpm and < 70 bpm and 28.5% in the HR
70 bpm group (p<.001).
We performed a multivariate analysis adjusted for age, diabetes, tobacco
consumption (none; 40 pack-years; > 40 pack-years), left ventricular ejection
fraction (>0.5; 0.5 and > 0.35; 0.35), duration of CAD, ankle-brachial index
(> 0.9; 0.9 and > 0.6; 0.6), history of chronic obstructive pulmonary disease
or stroke, statin therapy and coronary revascularization. For every 5 bpm
increase in resting heart rate, there was a significant 11% increase in all-cause
death (95% CI [4%; 18%] p=0.002).
Conclusion: HR is a strong and independent long term predictor factor of
all-cause death in CAD. A close control of HR should be promoted to improve
long term prognosis in coronary pts.
EES PES P
All cause death 2.9% 6.4% 0.13
Cardiac death 1.2% 4.7% 0.05
Target vessel myocardial infarction 4.1% 8.7% 0.08
Clinically driven target-lesion revascularization 2.9% 5.8% 0.19
Clinically indicated target vessel 
revascularization
7.0% 13.4% 0.05
Target lesion failure 6.4% 14.0% 0.02
MACE 8.1% 16.3% 0.02
Device-oriented composite 
Cardiac death+MI-TLR
6.4% 16.3% 0.004
Stent thrombosis 1.2% 6.4% 0.01
HIV+
(n=103)
HIV– 
(n=195)
Univariate
Hazard ratio
[95% CI]*
Major adverse cardiac events 17 (16.8†) 29 (15.1†) 1.4 [0.7-2.6]
Cardiovascular death 2 (3.0†) 3 (1.6†) 2.0 [0.4-9.9]
Recurrent ACS 12 (11.9†) 11 (5.8†) 3.4 [1.3-8.8]
Recurrent coronary 
revascularization
12 (11.8†) 24 (12.6†) 1.1 [0.5-2.2]
Target lesion revascularization 8 (7.8†) 17 (9.0†) 0.9 [0.4-2.1]
Target vessel revascularization 11 (10.8†) 20 (10.5†) 1.1 [0.5-2.3]
